107 related articles for article (PubMed ID: 1560437)
1. Cholesterol lowering bile acid binding agents: novel lipophilic polyamines.
Thomas EW; Cudahy MM; Spilman CH; Dinh DM; Watkins TL; Vidmar TJ
J Med Chem; 1992 Apr; 35(7):1233-45. PubMed ID: 1560437
[TBL] [Abstract][Full Text] [Related]
2. Effects of colestipol hydrochloride on cholesterol and bile acids absorption in the rat intestinal tract.
Fujihashi T; Munekiyo K; Meshi T
J Pharmacobiodyn; 1981 Aug; 4(8):552-8. PubMed ID: 7299619
[TBL] [Abstract][Full Text] [Related]
3. Hypocholesterolemic activity of colestipol hydrochloride in SEA quail.
Day CE
Artery; 1989; 17(1):49-59. PubMed ID: 2589993
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and colestipol hydrochloride in cholesterol fed SEA quail.
Day CE
Artery; 1990; 17(5):281-8. PubMed ID: 2396902
[TBL] [Abstract][Full Text] [Related]
5. Long-term cholesterol-lowering effect of colestipol resin in humans.
Gross L; Figueredo R
J Am Geriatr Soc; 1973 Dec; 21(12):552-6. PubMed ID: 4584170
[No Abstract] [Full Text] [Related]
6. Effect of enzymatic hydrolysis on cholesterol-lowering activity of oat beta-glucan.
Bae IY; Kim SM; Lee S; Lee HG
N Biotechnol; 2010 Feb; 27(1):85-8. PubMed ID: 19931657
[TBL] [Abstract][Full Text] [Related]
7. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
8. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans.
Hillebrant CG; Nyberg B; Einarsson K; Eriksson M
Gut; 1997 Nov; 41(5):700-4. PubMed ID: 9414982
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of colestipol (U-26,597 A) on plasma lipids in familial type II hyperbetalipoproteinaemia.
Fellin R; Briani G; Balestrieri P; Baggio G; Baiocchi MR; Crepaldi G
Atherosclerosis; 1975; 22(3):431-45. PubMed ID: 1201145
[TBL] [Abstract][Full Text] [Related]
10. The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man.
Goodman DS; Noble RP; Dell RB
J Clin Invest; 1973 Oct; 52(10):2646-55. PubMed ID: 4729058
[TBL] [Abstract][Full Text] [Related]
11. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism.
Einarsson K; Ericsson S; Ewerth S; Reihnér E; Rudling M; Ståhlberg D; Angelin B
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S53-8. PubMed ID: 2044645
[TBL] [Abstract][Full Text] [Related]
12. (1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor.
Fung AK; Baker WR; Fakhoury S; Stein HH; Cohen J; Donner BG; Garvey DS; Spina KP; Rosenberg SH
J Med Chem; 1997 Jul; 40(14):2123-5. PubMed ID: 9216829
[No Abstract] [Full Text] [Related]
13. Effect of crilvastatin, a new cholesterol lowering agent, on unesterified LDL-cholesterol metabolism into bile salts by rat isolated hepatocytes.
Clerc T; Sbarra V; Diaconescu N; Lafont H; Jadot G; Laruelle C; Chanussot F
Br J Pharmacol; 1995 Feb; 114(3):624-31. PubMed ID: 7735689
[TBL] [Abstract][Full Text] [Related]
14. The effects of colestipol on the metabolism of very-low-density lipoproteins in man.
Witztum JL; Schonfeld G; Weidman SW
J Lab Clin Med; 1976 Dec; 88(6):1008-18. PubMed ID: 186544
[TBL] [Abstract][Full Text] [Related]
15. Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the rat.
Phillips WA; Elfring GL
Lipids; 1977 Jan; 12(1):10-5. PubMed ID: 834115
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).
Tremont SJ; Lee LF; Huang HC; Keller BT; Banerjee SC; Both SR; Carpenter AJ; Wang CC; Garland DJ; Huang W; Jones C; Koeller KJ; Kolodziej SA; Li J; Manning RE; Mahoney MW; Miller RE; Mischke DA; Rath NP; Fletcher T; Reinhard EJ; Tollefson MB; Vernier WF; Wagner GM; Rapp SR; Beaudry J; Glenn K; Regina K; Schuh JR; Smith ME; Trivedi JS; Reitz DB
J Med Chem; 2005 Sep; 48(18):5837-52. PubMed ID: 16134950
[TBL] [Abstract][Full Text] [Related]
17. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.
Vega GL; Grundy SM
JAMA; 1987 Jan; 257(1):33-8. PubMed ID: 3537351
[TBL] [Abstract][Full Text] [Related]
18. Interaction of bile acids and cholesterol with non-systemic agents having hypocholesterolemic properties.
Stedronsky ER
Biochim Biophys Acta; 1994 Jan; 1210(3):255-87. PubMed ID: 8305482
[No Abstract] [Full Text] [Related]
19. Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents.
Magnin DR; Biller SA; Wetterau J; Robl JA; Dickson JK; Taunk P; Harrity TW; Lawrence RM; Sun CQ; Wang T; Logan J; Fryszman O; Connolly F; Jolibois K; Kunselman L
Bioorg Med Chem Lett; 2003 Apr; 13(7):1337-40. PubMed ID: 12657277
[TBL] [Abstract][Full Text] [Related]
20. Colestipol hydrochloride, a new hypolipidemic drug: a two-year study.
Cooper EE; Michel AM
South Med J; 1975 Mar; 68(3):303-9. PubMed ID: 1091001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
